Table 4.
Subsequent therapy in patients in Canada and the ITT population
| Subsequent therapy | Patients in Canada | ITT population | ||
|---|---|---|---|---|
| nab-P + Gem (n = 33) | Gem (n = 30) | nab-P + Gem (n = 431) | Gem (n = 430) | |
| Patients with any subsequent therapy, n (%) | 10 (30) | 13 (43) | 162 (38) | 179 (42) |
| 5-FU/Cape-based | 9 (27) | 11 (37) | 131 (30) | 155 (36) |
| FOLFIRINOX (modified/unmodified) | 2 (6) | 3 (10) | 19 (4) | 25 (6) |
| Other | 2 (6) | 3 (10) | 43 (10) | 50 (12) |
| Erlotinib-based | 1 (3) | 0 | 13 (3) | 11 (3) |
5-FU 5-fluorouracil; Cape capecitabine; FOLFIRINOX leucovorin, 5-FU, irinotecan, oxaliplatin; Gem gemcitabine; ITT intent-to-treat; nab-P nab-paclitaxel